



SPAFID  
CONNECT

Informazione Regolamentata n. 20106-58-2021	Data/Ora Ricezione 16 Novembre 2021 07:53:34	Euronext Star Milan
---	--	---------------------

Societa' : PHARMANUTRA  
Identificativo : 154256  
Informazione  
Regolamentata  
Nome utilizzatore : PHARMANUTRAN02 - Lacorte Roberto  
Tipologia : REGEM  
Data/Ora Ricezione : 16 Novembre 2021 07:53:34  
Data/Ora Inizio : 16 Novembre 2021 07:53:35  
Diffusione presunta  
Oggetto : PR - PHARMANUTRA SPA Distribution  
agreement Argentina

*Testo del comunicato*

Vedi allegato.

## PHARMANUTRA S.P.A.: NEW INTERNATIONAL AGREEMENT FOR THE DISTRIBUTION OF SIDERAL® IN ARGENTINA

**Pharmaceuticals company Laboratorios Ariston will introduce the Sucrosomial® Technology and SiderAL® brand in the Argentinian market, where the pharma industry is one of the main strategic investment sectors for the country.**

Pisa, 16 November 2021 – [PharmaNutra S.p.A.](#) (MTA; Ticker PHN), a company specialising in mineral-based nutritional supplements and medical devices for muscles and joints, has signed a new international distribution agreement for its SiderAL® products, the oral iron nutritional supplements leading the Italian nutraceutical market.

The agreement with Laboratorios Ariston covers the distribution in Argentina - a leading country in the haematology and gastroenterology fields - of SiderAL® Forte 20 Capsules 30mg Sucrosomial® Iron, a nutritional supplement based on Sucrosomial® Iron, PharmaNutra's innovative patent that reduces the side effects commonly associated with iron intake.

Established in 1949, Laboratorios Ariston operates throughout Latin America, marketing a total of 53 products in different fields including haematology, gastroenterology, gynaecology, urology, neurology, psychiatry, rheumatology and traumatology.

Brazil, Mexico, Bolivia and now Argentina: the agreement with Laboratorios Ariston strengthens PharmaNutra presence in Latin America, a market with huge potential; a key element in the international strategic plan aimed at achieving a leadership position in the oral iron market in Central and South America as well.

*"The agreement flanks our well-established presence in Brazil and more recent partnerships in Bolivia and Mexico, and also offers important prospects for the future," said PharmaNutra COO Carlo Volpi. "We intend to expand our collaboration with Laboratorios Ariston to other products of our portfolio and to other South American countries. This agreement is just the first step in a long and satisfying journey."*

*"Our company's commercial growth stems from its excellence in R&D and the agreement with Laboratorios Ariston is yet another example of this," added Scientific Director Germano Tarantino. "The contact originated through an Argentinian Key Opinion Leader at an international scientific meeting, confirming once again the worldwide recognition of our scientific patents and products. This is one of the main reasons for our constant international expansion."*

**PharmaNutra S.p.A.**

Founded and led by Chair Andrea Lacorte and Deputy Chair Roberto Lacorte, PharmaNutra, established in 2003, develops unique nutraceuticals and innovative medical devices, overseeing the entire production process from the proprietary raw materials to the finished product. The effectiveness of its products has been demonstrated by extensive scientific evidence, including more than 140 published papers. The Group has distribution and sales operations in Italy and abroad. In Italy, sales are conducted through a network of more than 150 medical representatives, who also handle exclusive marketing of PharmaNutra products to pharmacies all over the country. International sales in more than 50 countries are managed through 39 partners selected from top pharmaceutical companies. PharmaNutra is the leading producer of SiderAL® iron-based nutritional supplements, an area where it holds important patents for Sucrosomial® Technology. Over the years, the Group has developed a specific intellectual property production and management strategy, based on integrated management of all components: proprietary raw materials, patents, trademarks and clinical data.

[PharmaNutra.it](http://PharmaNutra.it)

For further information:

**PharmaNutra S.p.A.**

Via Delle Lenze, 216/b - 56122 Pisa  
Tel. +39 050 7846500

[investorrelation@pharmanutra.it](mailto:investorrelation@pharmanutra.it)

Internal Press Office

[press@calabughi.com](mailto:press@calabughi.com)

**Press Office - Spriano Communication & Partners**

Via Santa Radegonda, 16 - 20121 Milan  
Tel. +39 02 83635708

Matteo Russo

[mrusso@sprianocommunication.com](mailto:mrusso@sprianocommunication.com)

Cristina Tronconi

[ctronconi@sprianocommunication.com](mailto:ctronconi@sprianocommunication.com)

Fine Comunicato n.20106-58

Numero di Pagine: 4